Preview

Rational Pharmacotherapy in Cardiology

Advanced search

EVALUATION OF RANOLAZINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC STABLE ANGINA. RESULTS FROM THE TERISA RANDOMIZED CLINICAL TRIAL (TYPE 2 DIABETES EVALUATION OF RANOLAZINE IN SUBJECTS WITH CHRONIC STABLE ANGINA)

, , , , , , , , , , ,

Full Text:

Abstract

.

About the Authors



United States




United States




United States




United States




United States




United States




United States




Israel




United States




United States




United States




United States


References

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2013 update: a report from the American Heart Association. Circulation 2013;127:e6–245.

2. Brown N, Melville M, Gray D, et al. Quality of life four years after acute myocardial infarction: short form 36 scores compared with a normal population. Heart 1999;81:352–8.

3. Brorsson B, Bernstein SJ, Brook RH, Werko L. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart 2002;87:140–5.

4. Arnold SV, Morrow DA, Lei Y, et al. Economic impact of angina after an acute coronary syndrome: insights from the MERLIN-TIMI 36 trial. Circ Cardiovasc Qual Outcomes 2009;2:344–3.

5. Beltrame JF, Weekes AJ, Morgan C, Tavella R, Spertus JA. The prevalence of weekly angina among patients with chronic stable angina in primary care practices: the Coronary Artery Disease in General Practice (CADENCE) study. Arch Intern Med 2009;169:1491–9.

6. Maddox TM, Reid KJ, Spertus JA, et al. Angina at 1 year after myocardial infarction: prevalence and associated findings. Arch Intern Med 2008;168:1310–6.

7. Duarte R, Castela S, Reis RP, et al. Acute coronary syndrome in a diabetic population—risk factors and clinical and angiographic characteristics. Rev Port Cardiol 2003;22:1077–88.

8. Herlitz J, Wognsen GB, Emanuelsson H, et al. Mortality and morbidity in diabetic and nondiabetic patients during a 2-year period after coronary artery bypass grafting. Diabetes Care 1996;19:698–703.

9. Peterson PN, Spertus JA, Magid DJ, et al. The impact of diabetes on one-year health status outcomes following acute coronary syndromes. BMC Cardiovasc Disord 2006;6:41.

10. Morrow DA, Scirica BM, Chaitman BR, et al. Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial. Circulation 2009;119:2032–9.

11. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004;110:904–10.

12. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375–82.

13. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005;95:311–6.

14. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004;291:309–16.

15. Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol 2006;48:566–75.

16. Chisholm JW, Goldfine AB, Dhalla AK, et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 2010;33: 1163–8.

17. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006;27:42–8.

18. Ware JE Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.

19. Guy W. ECDEU Assessment Manual for Psychopharmacology (DHEW Publication No. ADM 76–338). Washington, DC: U.S. Government Printing Office, 1976.

20. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–34.

21. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007;298:765–75.

22. Marchant B, Umachandran V, Stevenson R, Kopelman PG, Timmis AD. Silent myocardial ischemia: role of subclinical neuropathy in patients with and without diabetes. J Am Coll Cardiol 1993;22:1433–7.

23. Murray DP, O’Brien T, Mulrooney R, O’Sullivan DJ. Autonomic dysfunction and silent myocardial ischaemia on exercise testing in diabetes mellitus. Diabet Med 1990;7:580–4.

24. Chiariello M, Indolfi C, Cotecchia MR, Sifola C, Romano M, Condorelli M. Asymptomatic transient ST changes during ambulatory ECG monitoring in diabetic patients. Am Heart J 1985;110:529–34.

25. Nishio S, Teshima Y, Takahashi N, et al. Activation of CaMKII as a key regulator of reactive oxygen species production in diabetic rat heart. J Mol Cell Cardiol 2012;52:1103–11.

26. Koval OM, Snyder JS, Wolf RM, et al. Ca2+/calmodulin-dependent protein kinase II-based regulation of voltage-gated Na+ channel in cardiac disease. Circulation 2012;126:2084–94.

27. Yao L, Fan P, Jiang Z, et al. Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventric- ular myocytes and N1325S mice. Am J Physiol Cell Physiol 2011;301:C577–86.

28. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008;117:1610–9.

29. Jackson G, Schwartz J, Kates RE, Winchester M, Harrison DC. Atenolol: once-daily cardioselective beta blockade for angina pectoris. Circulation 1980;61:555–60.

30. Weiss R, Ferry D, Pickering E, et al. Effectiveness of three different doses of carvedilol for exertional angina. Carvedilol-Angina Study Group. Am J Cardiol 1998;82:927–31.

31. Estrada JN, Saglietti H, Di Marco M, Casabe H, Oliveri R. Antiischemic properties of amlodipine, a new calcium antagonist, in patients with severe coronary artery disease: a prospective trial. Am Heart J 1989;118:1130–2.

32. Tardif JC, Ponikowski P, Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chron- ic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J 2009;30:540–8.

33. Frishman WH, Heiman M. Usefulness of oral nisoldipine for stable angina pectoris. The Nisoldipine Multicenter Angina Study Group. Am J Cardiol 1991;68:1004–9.

34. Stone AA, Shiffman S, Schwartz JE, Broderick JE, Hufford MR. Patient non-compliance with paper diaries. BMJ 2002;324:1193–4.

35. Arnold SV, Morrow DA, Wang K, et al. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial. Circ Cardiovasc Qual Outcomes 2008;1:107–15.


For citation:


., ., ., ., ., ., ., ., ., ., ., . EVALUATION OF RANOLAZINE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC STABLE ANGINA. RESULTS FROM THE TERISA RANDOMIZED CLINICAL TRIAL (TYPE 2 DIABETES EVALUATION OF RANOLAZINE IN SUBJECTS WITH CHRONIC STABLE ANGINA). Rational Pharmacotherapy in Cardiology. 2013;9(3):323-332. (In Russ.)

Views: 355


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)